Literature DB >> 25173967

Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis.

Beatriz Lozano-Ruiz1, Victoria Bachiller1, Irma García-Martínez1, Pedro Zapater2, Isabel Gómez-Hurtado1, Alba Moratalla1, Paula Giménez1, Pablo Bellot1, Rubén Francés3, José Such4, José M González-Navajas5.   

Abstract

BACKGROUND & AIMS: Inflammation is a common event in the pathogenesis of liver cirrhosis. The inflammasome pathway has acquired significant relevance in the pathogenesis of inflammation, but its role in the inflammatory response in patients with decompensated cirrhosis remains unexplored.
METHODS: We performed a prospective study in which 44 patients with decompensated cirrhosis and 12 healthy volunteers were included. We isolated macrophages from blood and ascitic fluid and assessed the expression and activation of the inflammasome, its response to priming by bacterial products, and its association with the degree of liver disease.
RESULTS: Macrophages from sterile ascitic fluids showed constitutive activation of caspase-1 and a marked increase in the expression of IL-1β, IL-18, and absent in melanoma 2 (AIM2) when compared to blood macrophages. Pre-stimulation of blood-derived macrophages from cirrhotic patients with bacterial DNA increased the expression of AIM2 and induced a higher AIM2-mediated inflammasome response than priming with other bacterial products such as lipopolysaccharide. By contrast, activation of the AIM2 inflammasome did not require a priming signal in ascitic fluid-derived macrophages, demonstrating the preactivated state of the inflammasome in these cells. Last, higher IL-1β and IL-18 production by ascitic fluid macrophages correlated with a more advanced Child-Pugh score.
CONCLUSIONS: The inflammasome is highly activated in the ascitic fluid of cirrhotic patients, which may explain the exacerbated inflammatory response observed in these patients under non-infected conditions. Clinically, activation of the inflammasome is associated with a higher degree of liver disease.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Absent in melanoma 2; Ascitic fluid; Inflammasome

Mesh:

Substances:

Year:  2014        PMID: 25173967     DOI: 10.1016/j.jhep.2014.08.027

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity.

Authors:  Si Ming Man; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Eur J Immunol       Date:  2015-12-28       Impact factor: 5.532

2.  Inflammasome activation in decompensated liver cirrhosis.

Authors:  José M González-Navajas
Journal:  World J Hepatol       Date:  2016-02-08

Review 3.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

Review 4.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

Review 5.  Role of AIM2 inflammasome in inflammatory diseases, cancer and infection.

Authors:  Bhesh Raj Sharma; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Eur J Immunol       Date:  2019-08-14       Impact factor: 5.532

6.  Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever.

Authors:  Nikolaos K Gatselis; Panagiotis Skendros; Konstantinos Ritis; George N Dalekos
Journal:  BMJ Case Rep       Date:  2016-09-22

Review 7.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

Review 8.  Inflammatory status in human hepatic cirrhosis.

Authors:  María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 9.  Inflammasomes in Cancer Progression and Anti-Tumor Immunity.

Authors:  Sebastian Lillo; Maya Saleh
Journal:  Front Cell Dev Biol       Date:  2022-04-20

Review 10.  The digestive tract as the origin of systemic inflammation.

Authors:  Petrus R de Jong; José M González-Navajas; Nicolaas J G Jansen
Journal:  Crit Care       Date:  2016-10-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.